EPAS1 and hepatocellular carcinoma: Similarly, NKT2152 is an orally administered HIF2α inhibitor demonstrating potent reduction in tumor growth in murine preclinical models of clear cell renal cell carcinoma (ccRCC) and other solid tumors including HCC.